Phenylketonuria
Conditions
Brief summary
The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
Interventions
DRUGAG-181
AG-181 film-coated tablets
Sponsors
Agios Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Diagnosis of PKU, defined as documented presence of 2 mutant alleles in the phenylalanine hydroxylase (PAH) gene, of which at least 1 is the R408W mutation, as determined during Screening per the genotyping performed by the study central genotyping laboratory. * At least 1 plasma Phe concentration greater than (\>) 600 micromoles per liter (μmol/L) in the 52 weeks before providing informed consent. * Average concentration of plasma Phe \> 600 μmol/L in Phe samples taken during Screening, with no individual assessment below 360 μmol/L. Any Phe samples taken after Day -20 will not be included. * Body mass index (BMI) greater than or equal to (≥) 18.0 kilograms per meter square (kg/m\^2) to lesser than or equal to (≤) 35.0 kg/m\^2 and weight ≥ 50 kilograms (kg) at any time during the Screening Period. * Documented approval from a dietitian confirming that the subject can maintain their diet consistent in protein and Phe intake throughout the study as outlined in the Diet Manual. Key
Exclusion criteria
* Prior exposure to AG-181. * Receiving inhibitors of P-glycoprotein (P-gp) that have not been stopped for ≥ 5 days or a timeframe equivalent to 5 half-lives (whichever is longer) before administration of the first dose of study drug. * Receiving products that are strong inhibitors or strong inducers of cytochrome P450 CYP1A2, CYP2C8, or CYP3A that have not been stopped for ≥ 28 days before administration of the first dose of study drug. * Receiving treatment with an acid-reducing agent, including but not limited to proton pump inhibitors and H2 blockers. Short-acting acid-reducing agents such as calcium carbonate are permitted. * Any preexisting condition that could (in the opinion of the Investigator) interfere with gastrointestinal anatomy or motility that may disrupt the absorption, metabolism, and/or excretion of the study drug. * Any preexisting condition that could (in the opinion of the Investigator) interfere with hepatic or renal function that may disrupt the absorption, metabolism, and/or excretion of the study drug. * Inability to tolerate oral medication. * Unwillingness to washout from tetrahydrobiopterin (BH4) supplementation (eg, sapropterin dihydrochloride, Kuvan), pegvaliase-pqpz (Palynziq), or any other PKU therapy by Day -30 during Screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Type, Severity, and Relationship to the Study Drug | Up to Day 42 |
Secondary
| Measure | Time frame |
|---|---|
| Plasma Concentration of AG-181 | Up to Day 28 |
| Maximum Concentration (Cmax) of AG-181 | Up to Day 28 |
| Time to Maximum (Peak) Concentration (Tmax) of AG-181 | Up to Day 28 |
| Area Under the Concentration-Time Curve (AUC) of AG-181 | Up to Day 28 |
| Apparent Total Body Clearance (CL/F) of AG-181 | Up to Day 28 |
| Apparent Volume of Distribution in the Terminal Phase (Vz/F) of AG-181 | Up to Day 28 |
| Change From Baseline in Phenylalanine (Phe) Concentration | Baseline up to Day 28 |
Countries
Poland, United States
Contacts
CONTACTAgios Medical Affairs
Outcome results
None listed